Literature DB >> 9236525

Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis.

C Paul1, A Le Tourneau, J M Cayuela, A Devidas, C Robert, V Molinié, L Dubertret.   

Abstract

BACKGROUND: Epstein-Barr virus (EBV)-associated lymphoproliferative disorders have recently been observed during treatment of rheumatoid arthritis and dermatomyositis with low-dose methotrexate. OBSERVATION: A patient with psoriasis developed a B-cell lymphoproliferative disorder during long-term treatment with low-dose methotrexate. The lymphoid cells expressed EBV latent membrane protein 1, and the EBV viral genome was present as demonstrated by in situ hybridization. Evaluation for EBV clonality showed that the lymph node contained clonal EBV DNA. Polymerase chain reaction studies confirmed that the B-cell lymphoproliferative disorder was mainly monoclonal, suggesting that the disorder arose from a single EBV-infected B-cell clone.
CONCLUSIONS: Lymphoproliferative disorders associated with Epstein-Barr virus in which the clinicopathological presentation is similar to those occurring in patients after transplantation may be observed in patients with psoriasis treated with methotrexate. While it is impossible to rule out a fortuitous occurrence of an EBV-associated lymphoproliferative disorder and psoriasis treated with methotrexate in the same patient, EBV appears to be critical in the pathogenesis of the lymphoproliferative disorder in this patient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236525

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

2.  Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus.

Authors:  Eric J Yager; In-Jeong Kim; Michael L Freeman; Kathleen G Lanzer; Claire E Burkum; Tres Cookenham; David L Woodland; Marcia A Blackman
Journal:  Immun Ageing       Date:  2010-02-02       Impact factor: 6.400

Review 3.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

Review 4.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.

Authors:  Rachael L Gross; Julie S Schwartzman-Morris; Michael Krathen; George Reed; Hong Chang; Katherine C Saunders; Mark C Fisher; Jeffrey D Greenberg; Chaim Putterman; Philip J Mease; Alice B Gottlieb; Joel M Kremer; Anna Broder
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

Review 6.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

7.  Lymphoma masquerading as occlusive retinal vasculitis: A case study.

Authors:  Scott J Sonne; Wen-Shi Shieh; Sunil K Srivastava; Bradley T Smith
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.